Pharma Veteran Vishal Shah Joins Algorae as CCO

Algorae Pharmaceuticals Limited is excited to announce the appointment of Vishal Shah as Chief Commercial Officer (CCO). With over 20 years of experience in pharmaceuticals, biotechnology, and healthcare, Shah will lead Algorae’s commercial strategy, focusing on growth, market expansion, and strategic partnerships.

A Proven Leader in the Pharmaceutical Industry

Shah joins Algorae from HPS Pharmacies, a division of EBOS Group Ltd (ASX: EBO)—Australasia’s largest pharmaceutical wholesaler and distributor. During his tenure, he played a key role in shaping procurement strategies, driving revenue growth, and expanding market reach. His leadership helped solidify the company's market position and establish high-value industry partnerships.

“We are thrilled to welcome Vishal to Algorae,” said David Hainsworth, Executive Chairman. “His experience in scaling pharmaceutical businesses, forging strategic partnerships, and driving revenue growth will be instrumental in bringing Algorae’s AI-driven innovations to market.”

A Track Record of Success

Before EBOS, Shah held senior leadership roles at Baxter Healthcare (NYSE: BAX), including:

• Associate Director of Pharmaceuticals for Asia-Pacific (APAC)

• Head of Pharmaceuticals for Australia/New Zealand (ANZ)

At Baxter—a global leader in medical technology and pharmaceuticals with a market capitalization of A$27 billion—he successfully led commercial strategies, product launches, and growth initiatives, driving both revenue and profitability. His expertise includes:

✅ Navigating regulatory landscapes 

✅ Establishing strategic alliances

✅ Optimizing commercial operations across global markets

Excited for the Future

“I’m excited to join Algorae at such a pivotal time,” said Vishal Shah. “With its AI-driven pharmaceutical strategy, Algorae has a unique competitive edge in transforming drug development and market penetration. I look forward to working with the team to drive commercial success and expand our impact.”

Beyond his corporate leadership, Shah is actively shaping the future of healthcare innovation. As a member of the Advisory Committee for Access Capital Venture in Australia, he provides strategic guidance to emerging health-tech startups, helping them navigate commercialization and market entry.

A Strong Scientific and Business Foundation

Shah holds a Pharmacy Degree, a Master’s in Applied Science (Biotechnology), and an MBA from Western Sydney University, equipping him with the scientific expertise and commercial acumen necessary for his role at Algorae.

With this appointment, Algorae is poised for stronger market growth and industry leadership as it continues to revolutionize drug development through AI-driven innovation.